Tumor growth suppression by gadolinium-neutron capture therapy using gadolinium-entrapped liposome as gadolinium delivery agent

Biomedicine and Pharmacotherapy

Volumn 67, Issue 6, 2013, Pages 451-457

  Dewi, Novriana ^a   Yanagie, Hironobu ^a,b   Zhu, Haito ^a   Demachi, Kazuyuki ^a   Shinohara, Atsuko ^c   Yokoyama, Kazuhito ^d   Sekino, Masaki ^a   Sakurai, Yuriko ^b   Morishita, Yasuyuki ^e   Iyomoto, Naoko ^f   Nagasaki, Takeshi ^g   Horiguchi, Yukichi ^h   Nagasaki, Yukio ^h   Nakajima, Jun ^b   Ono, Minoru ^b   Kakimi, Kazuhiro ^b   Takahashi, Hiroyuki ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c Seisen University   (Japan)

^d JUNTENDO UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f KYUSHU UNIVERSITY   (Japan)

^g Osaka Prefecture University   (Japan)

^h UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Drug delivery system; Gadolinium; Liposome; Neutron capture therapy

Indexed keywords

GADOTERIDOL; LIPOSOME;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; IN VIVO STUDY; MOUSE; NEUTRON CAPTURE THERAPY; NEUTRON RADIATION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUMOR GROWTH;

DRUG DELIVERY SYSTEM; GADOLINIUM; LIPOSOME; NEUTRON CAPTURE THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; BORON; DRUG DELIVERY SYSTEMS; GADOLINIUM; JAPAN; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS; NEUTRON CAPTURE THERAPY;

EID: 84880930693     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.11.010     Document Type: Article

References (26)

1. Brugger R.M., Shih J.A. Evaluation of gadolinium-157 as a neutron capture therapy agent. Strahlenther Onkol 1989, 165:15356.
2. Masiakowski J.T., Horton J.L., Peters L.J. Gadolinium-neutron capture therapy for brain tumors: a computer study. Med Phys 1992, 19:127784.
3. Takagaki M., Hosmane N.S. Gadolinium-neutron capture therapy for malignant brain tumors. Aino J 2007, 6:39-44.
4. De Stasio G., et al. Are gadolinium contrast agents suitable for gadolinium-neutron capture therapy?. Neurol Res 2005, 27:387-398.
5. Cerullo N., Bufalino D., Daquino G. Progress in the use of gadolinium for NCT. Appl Rad Isot 2009, 67:S157-S160.
6. Le U.M., Cui Z. Long-circulating gadolinium-encapsulated liposomes for potential application in tumor neutron capture therapy. Int J Pharm 2006, 312:105-112.
7. Yanagie H., et al. Application of drug delivery system to boron neutron capture therapy for cancer. Expert Opin Drug Deliv 2008, 5(4):427-443.
8. Yanagie H., et al. Application of boronated anti-CEA immunoliposome to tumour cell growth inhibition in in vitro boron neutron capture therapy model. Br J Cancer 1991, 63(4):522-526.
9. Yanagie H., et al. Inhibition of human pancreatic cancer growth in nude mice by boron neutron capture therapy. Br J Cancer 1997, 75:6605.
10. Yanagie H., et al. Inhibition of growth of human breast cancer cells in culture by neutron capture using liposomes containing 10B. Biomed Pharmacother 2002, 56(2):93-99.
11. Miyamoto M., et al. Biodistribution of gadolinium incorporated in lipid-emulsions intraperitoneally administered for neutron capture therapy with tumor-bearing hamsters. Biol Pharm Bull 1999, 22:1331-1340.
12. Awasthi V.D., et al. Neutral and anionic liposome-encapsulated hemoglobin: effect of postinserted poly(ethylene glycol)-distearoylphosphatidylethanolamine on distribution and circulation kinetic. J Pharmacol Exp Ther 2004, 309:241-248.
13. Burger P.C., et al. Glioblastoma multiforme and anaplastic astrocytoma pathologic criteria and prognostic implications. Cancer 1985, 56(5):1106-1111.
14. Bruner J.M. Neuropathology of malignant gliomas. Semin Oncol 1994, 21(2):126-138.
15. Barth R.F., et al. Boron neutron capture therapy of cancer. Cancer Res 1990, 50:1061.
16. De Stasio G., et al. Gadolinium in human glioblastoma cells for gadolinium-neutron capture therapy. Cancer Res 2001, 61:4272-4277.
17. 157Gd neutron capture. Pigment Cell Res 1989, 2:3302.
18. Hofmann B., et al. Gadolinium-neutron capture therapy (Gd-NCT) of melanoma cells and solid tumors with the magnetic resonance imaging contrast agent Gadobutrol. Invest Radiol 1999, 34:126-133.
19. Khokhlov V.F., et al. Neutron capture therapy with Gd-DTPA in tumor-bearing rats. Cancer Neutron Capture Therapy 1996, 865-869. Plenum Press, New York. Y. Mishima (Ed.).
20. Birgit R., Wim E.H., Gert S. Sheddable coatings for long-circulating nanoparticles. Pharm Res 2008, 25(1):55-71.
21. Mehta S.C., Lai J.C., Lu D.R. Liposomal formulations containing sodiummercaptoundeca-hydrododecaborate (BSH) for boron neutron capture therapy. J Microencapsul 1996, 13(3):269-279.
22. Yanagie H., et al. Application of boron-entrapped stealth liposomes to inhibition of growth of tumor cells in the in vivo boron neutron capture therapy model. Biomed Pharmacother 2006, 60(1):43-50.
23. Maruyama K., et al. Intracellular targeting of sodium mercaptoundecahydro-dodecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron capture therapy (BNCT). J Control Release 2004, 98(2):195-207.
24. Yanagie H., et al. Evaluation of neutron dosimetry on pancreatic cancer phantom model for application of intraoperative boron neutron capture therapy. Biomed Pharmacother 2007, 61(8):505-514.
25. Runge V.M., et al. The use of Gd-DTPA as a perfusion agent and marker of blood brain barrier disruption. Magn Reson Imaging 1985, 3:43-55.
26. Yoshida K., et al. Assessment of T1 time course changes and tissue-blood ratios after Gd-DTPA administration in brain tumors. Magn Reson Imaging 1989, 7:9-15.